Dr. Tan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204Phone+1 980-442-2000
Summary
- Dr. Antoinette Tan is an oncologist in Charlotte, NC and is affiliated with Atrium Health's Levine Cancer Institute. She received her medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 23 years. She specializes in breast cancer and is experienced in breast cancer and medical oncology. She has more than 80 publications and over 500 citings.
Education & Training
Duke UniversityMHSc, Clinical Research, 2001 - 2002
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002- Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1996 - 1999
Rutgers Robert Wood Johnson Medical SchoolClass of 1996
Certifications & Licensure
NC State Medical License 2014 - 2025
NJ State Medical License 2001 - 2015- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.Erika Hamilton, Matthew D Galsky, Sebastian Ochsenreither, Gianluca Del Conte, Miguel Martín
Clinical Cancer Research. 2024-12-16 - Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.Rani Bansal, Tolulope Adeyelu, Andrew Elliott, Antoinette R Tan, Jennifer R Ribeiro
JCO Precision Oncology. 2024-12-01 - Interpretation of Reports and Translation to Community Oncologists: An Overview of Approaches.Carol J Farhangfar, Kathryn F Mileham, Antoinette R Tan
JCO Oncology Practice. 2024-11-01
Press Mentions
Clinical Challenges: When to Add Immunotherapy in Breast CancerOctober 14th, 2021
Subcutaneous Fixed-Dose and IV Pertuzumab/Trastuzumab Show Similar EfficacyDecember 13th, 2019- SABCS® Daily Highlights for Thursday, December 7December 20th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
